Massachusetts Question 8: What the Adult-Use Cannabis Repeal Would Change
Massachusetts Question 8 cannabis repeal: Massachusetts Question 8 would end licensed adult-use cannabis sales and home cultivation. Limited possession and the medical cannabis program would remain. This digest explains the official text, ballot status,…
Texas THC Ban Remains as Federal Judge Denies Emergency Pause
The Texas THC ban remains in place after a federal judge denied emergency relief. The broader hemp lawsuit and a preliminary-injunction request are still pending. CED explains what changed, what remains uncertain, and why legal availability does not…
Bipartisan Bill Proposes Federal Rules for Hemp THC Drinks
The Beverage Regulatory Parity Act would create federal rules for qualifying hemp THC drinks. The proposal includes a 5-milligram serving cap, age 21 sales, testing, labels, permits, and state authority. It is newly introduced legislation, not current…
Safe Sips Act Proposes a Federal Marker for Intoxicating Drinks
The Safe Sips Act would direct federal agencies to create a common marker for THC beverages and other intoxicating drinks. The introduced bill also proposes a non-color accessibility cue. It is not law and would not replace dose labels, safe storage, or…
What Happens After Cannabis Laws Change? A Review of 176 Policy Studies
Cannabis policy and substance use evidence from 176 quasi-experimental reports shows adult cannabis use often rises after liberalization. Alcohol, tobacco, opioid, and youth outcomes varied by policy and population. The review supports targeted…
German Cannabis Legalization Rollback: June 30, 2026 Update
German state interior ministers are moving to roll back federal cannabis legalization despite supporting evidence, potentially disrupting implementation and patient access. This policy shift reflects broader tensions between regulatory frameworks and…
Policy Watch: 20 Regulatory Updates — June 22, 2026
This update covers DEA synthetic opioids schedule I placement actions affecting clinical and regulatory landscapes in 2026. These changes influence substance classification and patient care considerations. Stay informed on the latest controlled…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products
The DEA rescheduling Schedule III cannabis marks a pivotal regulatory change for FDA approved cannabis products. This shift facilitates improved medical cannabis access under federal law. Clinicians and patients should understand the implications of this…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has issued the cumyl-pegaclone schedule i designation, reflecting its high abuse potential and lack of accepted medical use. This designation highlights regulatory efforts to control synthetic cannabinoids. Clinicians should be aware of the risks…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA has issued temporary scheduling orders placing 2-fluorodeschloroketamine into Schedule I. These orders address emerging synthetic drugs and their regulatory challenges. Temporary scheduling orders are critical for managing novel substances with…